Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer

被引:0
|
作者
Han Yang
Yongbin Lin
Ying Liang
机构
[1] Sun Yat-sen University Cancer Center,Department of Thoracic Surgery
[2] State Key Laboratory of Oncology in South China,Department of Medical Oncology
[3] Collaborative Innovation Center for Cancer Medicine,undefined
[4] Sun Yat-sen University Cancer Center,undefined
来源
Current Treatment Options in Oncology | 2017年 / 18卷
关键词
Lung carcinosarcoma; Primary pulmonary lymphoma; Pulmonary carcinoid; Primary pulmonary lymphoepithelioma-like carcinoma;
D O I
暂无
中图分类号
学科分类号
摘要
Lung carcinosarcoma (PCS) and other histological subtypes of non-small cell lung cancer, such as primary pulmonary lymphoma (PPL), pulmonary carcinoid (PC), and primary pulmonary lymphoepithelioma-like carcinoma (LELC), are rare. For their low incidence, the diagnosis and treatment are still controversial. Some patients only need surgery, while others may need chemotherapy, radiotherapy, or targeted therapy. In this paper, we retrospectively reviewed the literature of some rare histological subtype of NSCLC for the recent 20 years, and try to get some conclusions.
引用
收藏
相关论文
共 50 条
  • [21] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [22] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
  • [23] Current treatment of non-small cell lung cancer
    Tonato, M
    TUMORI JOURNAL, 2002, : S7 - S8
  • [24] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [25] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [26] Sintilimab for the treatment of non-small cell lung cancer
    Zhang, Lin
    Lin, Weihao
    Tan, Fengwei
    Li, Ning
    Xue, Qi
    Gao, Shugeng
    Gao, Yibo
    He, Jie
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [27] Pemetrexed in the treatment of non-small cell lung cancer
    Shepherd, FA
    SEMINARS IN ONCOLOGY, 2002, 29 (06) : 43 - 48
  • [28] Vinorelbine in the treatment of non-small cell lung cancer
    Gridelli, C
    De Vivo, R
    CURRENT MEDICINAL CHEMISTRY, 2002, 9 (08) : 879 - 891
  • [29] Advances in treatment for non-small cell lung cancer
    Price, Katharine A.
    Jett, James R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (07) : 792 - 794
  • [30] Atezolizumab for the treatment of non-small cell lung cancer
    Santini, Fernando C.
    Rudin, Charles M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (09) : 935 - 945